Read time: 5 minutes

Welcome to the Succession newsletter where 2,000+ life science sales reps improve their skills in 5 minutes per week. If you’re getting value from these newsletters, we'd love it if you could forward it along to your sales colleagues. If you’re new here, subscribe below.

Succession Bio works with life science/biotech companies to help drive sales, licensing, and partnership opportunities.

We do this through market research to identify the right companies and people, craft scientifically credible messages, and then perform the outbound sales and marketing tactics on your behalf to facilitate meetings with the right people at the right companies.

Succession

• Specializes in life sciences/biotech (it's all we do!)

• Provides market research, messaging, and outbound sales/marketing services

• Facilitates meetings and opportunities with the right people at the right companies for our clients

• Sales training for teams of 10+ who want to find and close more deals with biotech and pharma

A biotech in your space announces a raise, your ears prick up, and within about ninety seconds you've got a blank email open with "Congratulations on the raise!" sitting at the top of it. They've got money now, you sell something they might need, and you're getting in early. Feels like the obvious move, after all your job is to get that bread.

But the problem is, there’s likely hundreds of other people who had the exact same ninety-second idea. On announcement day, a funded company's inbox turns into a receiving line of vendors, recruiters and bankers all clearing their throats with the same congratulations. The founder isn't reading any of it. They're doing press, fielding board calls, and panicking in the staff kitchen about whether they can actually deliver on what they just raised against. Your "congrats" lands in the pile and dies there.

Now, regular readers will know we're a bit sceptical of funding as a buying signal in the first place. I've said before that a raise doesn't mean a company is about to buy your category of thing, and that hiring signals are usually more reliable. I stand by that. But a raise is still a genuine moment, and played properly it's a real way in. The issue is that almost everyone reacts to the headline number instead of reading what's underneath it.

Because the number itself tells you very little. The useful information is one layer down: in what that money now forces the company to do. New cash means they have to hire, build, stand up functions they didn't have last month, and make a flurry of buying decisions on a timeline they didn't have last month either. That's the signal worth acting on. Not "they have money," but "here's the specific list of problems they've just signed up to solve, and roughly when."

Just look at the last couple of weeks. In a stretch of about ten days in mid-May, all of these landed:

• Isomorphic Labs raised a $2.1bn Series B (the Alphabet-spun AI drug-design company, led by Thrive Capital)

• cAMPfield Therapeutics came out of stealth with a $180m Series A for inflammation and immunology

• CREATE Medicines closed a $122m Series B for its in-vivo CAR-T pipeline

• Full-Life Technologies pulled together $150m to scale its radiotherapeutics pipeline and build out actinium-225 manufacturing

• Parabilis Medicines signed a research deal with Regeneron worth up to $2.3bn in milestones, then promptly filed to go public

Every one of those is "a biotech got funded." And every one is a completely different opportunity, with a different buyer, a different urgency, and a different right way in. Lump them together and you'll get all five wrong. So here's how to actually read one.

1. Read the round, not the number

The type of round tells you what kind of buying the company is about to do, and it should change your whole approach.

A Series A, especially one out of stealth like cAMPfield, means they're building the engine from scratch. No incumbent vendors, no entrenched processes, no "we already use someone for that." It's greenfield. Whoever they pick for their first CRO, their first data platform, their first specialist service, those slots are genuinely open right now in a way they'll never be again. You're not displacing anyone. You're being the first answer to a question they've only just started asking.

A late-stage round is the opposite. When Full-Life raises to scale manufacturing, they already have vendors and years of process behind them. You're trying to displace someone embedded, which is slower and more political, and where "we're cheaper" almost never wins. What wins is solving the new problem the scale-up creates, which we'll come to.

A pharma partnership is different again. When Parabilis signs with Regeneron, its priorities for the next two years just got set by Regeneron's programme, not its own roadmap. And filing for an IPO days later tells you even more: a company heading to the public markets is buttoning everything down and is allergic to anything that looks like a distraction. You'd pitch that very differently to a scrappy Series A.

Same word, "funded," three completely different companies to walk up to.

2. Anchor to the problem the money just created

This is the heart of it, and it's where "congrats" falls down. Congratulating someone is about the event. Being useful is about the consequence.

Money creates problems. Lovely problems, the kind founders are glad to have, but problems all the same. A company that raises $180m to build an I&I pipeline now has to hire dozens of people in a hurry, stand up functions it didn't have, and choose a stack of vendors fast, all before it has the operational muscle to do any of it smoothly. A company building actinium-225 manufacturing has a wildly specific and genuinely hard problem it wasn't dealing with at that scale last quarter. Those problems are your way in.

So don't anchor your message to your product. Anchor it to the gap the raise just opened:

Don’t do: "Congratulations on the $180M! We'd love to show you how our platform can support your growth."

Instead, do something more like this: "Saw the Series A. Building out an I&I pipeline that fast usually means [specific bottleneck] bites around month three, before the team's fully in place. We've helped a couple of groups through exactly that point. Worth a short chat now, before it's urgent?"

The second one only works if you genuinely understand what the money forces them to do. Which means the homework matters far more than the speed.

AI tip: This is exactly the kind of thinking Claude or ChatGPT is good at if you give it the right inputs. Gather three things first: the funding press release, the company's website (the pipeline/about pages especially), and their careers page, then paste them in with a prompt like this:

You're helping me plan outreach to a biotech that just raised money. I sell [describe what you offer in one line] to [your typical buyer].

Here's what I've gathered on the company:

- Funding announcement: [paste the press release]
- Website/pipeline: [paste key text from their site]
- Careers page: [paste current open roles]

Work through this in order and give me a short, practical plan:

1. The raise. What did they raise, what round, and what does that money commit them to delivering over the next 12-18 months?

2. Their goals. Based on the round type, the pipeline, and what they're hiring for, what are the 3-4 things this team is actually trying to get done right now?

3. The gaps. For each goal, what operational problem or capability gap does that create in the next 3-6 months — the kind of thing they'll need to buy or build to solve?

4. The fit. Which of those gaps does what I sell genuinely help with? Be honest. If I'm not a real fit for this company, tell me so I don't waste the effort.

5. The buyer. Based on their open roles and structure, who is most likely to own the budget for the gap I can help with? Give me a likely job title.

6. The message. Draft three short outreach openers (under 80 words each), each anchored to a specific gap and goal above — in their language, not mine. No "congrats on the raise". No leading with my product. Lead with the problem, then connect it to what I do.

For anything you're inferring rather than reading directly from the sources, say so.

Treat the output as a starting point for your own thinking, not a script to paste. The point is to do the homework fast, not to outsource the judgement.

3. The real signal is underneath the raise: who they're about to hire

This connects back to the point I keep banging on about. Funding is a loud signal but a blunt one. The sharp version sits underneath it: the roles a company posts in the weeks after a raise tell you, far more precisely than the press release ever will, what they're actually building and therefore what they're about to buy.

Harrison made the case a while back (#089) that job descriptions are one of the most underused buying signals going. A funding round is exactly when that comes alive. The raise tells you a company has money and intent. The job postings that follow tell you specifically what they're standing up and who will own the budget for it. The new Head of Whatever is your buyer, and on announcement day they often don't even exist yet.

So when you see a raise you care about, don't just fire off an email. Watch the careers page for the next few weeks. The hires are the leading indicator, and they tell you both what to say and who to say it to.

4. From signal to message: a few worked examples

The method is always the same three steps: read the signal, work out the goal it implies, then position the one part of your offering that moves them towards that goal. Most people do the first step and jump straight to pitching. The money is in the middle step.

Here's the translation running end to end on three of this fortnight's rounds. I've shown two different types of seller for each, to make the point that the same signal points different vendors at different angles, all of them legitimate.

cAMPfield: $180m Series A, out of stealth, in-licensing model in I&I

• What the signals say: brand new, well-funded, no existing infrastructure, and a strategy built on in-licensing assets from other companies rather than discovering their own.

• What that tells you they're trying to do: hire a foundational team fast, stand up operations from zero, and because they're in-licensing, rapidly and independently validate candidates they didn't generate, so they can pick winners and hit the early milestones that justify the raise.

• If you're a preclinical CRO, the in-licensing angle is gold. Anchor to independent characterisation of in-licensed assets:
  "Saw cAMPfield's launch. An in-licensing model lives or dies on how quickly you can independently validate assets you didn't generate in-house. We've run exactly that kind of fast, independent characterisation work for [similar I&I team] so they could de-risk their go/no-go calls early. Happy to share how they approached it if it's useful."

• If you sell an ELN or data platform, anchor to the one-time chance to set up clean infrastructure before the team scales:
  "For team’s coming out of stealth, the one thing that's far easier now than in twelve months' time is locking down how your data's structured before forty new people each invent their own way of doing it. We've helped a few teams set that foundation during exactly this build phase. Worth a quick look before the hiring ramps?"

Full-Life: $150m, scaling radiotherapeutics, building Ac-225 manufacturing

• What the signals say: later-stage, owns its value chain, and is pouring money into actinium-225 manufacturing specifically.

• What that tells you they're trying to do: de-risk a notoriously scarce isotope supply, scale GMP manufacturing, and keep multiple clinical programmes moving without a supply wobble derailing them.

• If you're in supply chain, CDMO or specialist logistics, anchor straight to the isotope and the scale-up:
  "The Ac-225 build-out is the part of your raise I'd want to talk about. Isotope supply and the cold chain around it is where most radiotherapeutics timelines tend to slip. We've worked with [comparable programme] on exactly that constraint. Can I send a short note on how they handled the supply risk as they scaled?"

• If you sell something with no link to manufacturing or supply, this is your cue to qualify out. A $150m headline doesn't make them your buyer. Move on (see section 6).

CREATE Medicines: $122m Series B, in-vivo CAR-T, expanding into autoimmune

• What the signals say: clinical-stage and scaling, the largest in-vivo CAR dataset in the field, and a deliberate push from oncology into autoimmune.

• What that tells you they're trying to do: run more and bigger trials, scale mRNA-LNP manufacturing to match, and stand up the capability to operate in a brand new therapeutic area.

• If you're a clinical trial or patient-recruitment partner, anchor to the indication expansion:
  "The move into autoimmune is a different recruitment and site-selection game than your oncology trials, different investigators, different patient pathways. We've helped teams making similar jumps. Worth comparing notes as you scope the next studies?"

• If you're in bioanalytical or manufacturing, anchor to scaling LNP production to keep pace with an expanding clinical footprint.

The pattern across all three: the signal narrows down what they care about, and your job is to say the one true thing about your offering that sits directly on top of that goal, in their language rather than yours. Notice none of these lead with the product. They lead with the problem the money just created, and only then connect it to what you do.

A note on the partnership case (Parabilis). When a company's just tied itself to a big pharma and filed to go public, it's heads-down on delivering partnered milestones and derisking for the markets. Outreach has to be exceptionally relevant or it reads as a distraction and gets binned. If you genuinely help hit a partnered programme's milestones, or shore up the quality and regulatory side ahead of an IPO, say exactly that and nothing else. If you don't, this isn't your moment.

5. The window opens later than you think

This is the most counterintuitive bit, so stay with me. The day of the announcement is the worst day to reach out, not the best.

On announcement day the company is doing press, not reading cold email, and the inbox is at peak noise. The actual buying happens a few weeks later, when the new budget turns into headcount, the headcount turns into requisitions, and the requisitions turn into purchase orders. That's your window, after the noise dies down, before the vendor decisions lock in, when they're finally thinking about the problem rather than fielding congratulations.

Being first isn't the goal. Being well-timed is. When you spot a round worth pursuing, diarise a reminder for two or three weeks out, do the homework in the meantime, and turn up when they're ready to listen. Most others will have given up by then anyway or wasted their shot with a “congrats on your funding please give me your money for the thing we sell” message.

6. Qualify hard, because most funded companies aren't your buyer

A funding round tells you when a company might be ready. It tells you nothing about whether they're a fit for you. Those are different questions, and chasing the first while ignoring the second is how you waste a fortnight.

Isomorphic raised $2.1bn. It's an AI-native company already partnered with Novartis, Lilly and J&J. For many of you reading this, it’s just another headline, not a prospect. Big numbers have a gravitational pull, and the discipline is to feel that pull and walk straight past it, because a $2.1bn raise that isn't your buyer is worth precisely nothing to you, and the hour you spend chasing it is an hour you didn't spend on the Series A that actually fits.

Run every funded company through the same honest filter you'd use on any list: right space, right size, right person, real reason they'd need your category right now. Most won't pass. The ones that do deserve all your attention. The ones that don't will burn your time, your focus, and (if you're emailing at volume) your domain reputation along with it.

7. Mine the investor list for a warm intro

This one's sitting in plain sight on the press release and almost nobody uses it. Look at who led these rounds and you'll see the same names again and again: RA Capital, Novo Holdings, ARCH, Vivo, Forbion, Frazier. These funds each back dozens of companies. If you already work with one company in a fund's portfolio and that fund just led a round in a company you want to reach, you've got a real warm path. A line from a portfolio company you've delivered well for, or an intro from a partner at the fund, is worth more than fifty perfect cold emails. The cap table is a relationship map, so use it to your advantage.

Tying it all together 

A raise isn't a reason to celebrate at someone. It's a set of clues: what they now have to do, when they'll have to do it, who they'll need to do it with, and who they're about to hire to make it happen. Read the clues, watch the hiring, time it properly, and turn up with something useful instead of a congratulations. Everyone else in their inbox is doing the opposite, which is exactly why it works.

One thing to try this week

Pick one company in your space that's raised in the last month. Don't email them yet. Instead: pull up their careers page and note what they're hiring for, work out the one operational problem that money most likely just created, and identify who would own the budget to fix it. Then draft a single message anchored to that problem, addressed to that person, to send in a week or two. Compare it to the "congrats on the raise" email you'd have sent on day one. I'd bet the difference is obvious.

And if you've got a funding-signal play that's worked well for you, reply and tell me. I'm always after good examples for inspiration.

As a final shameless plug, if you want to set up a whole host of signals-based campaigns alongside the standard ones, with scientifically credible messaging and highly-targeted lists, where all you have to do is pick up the lead after they respond positively, schedule a call with us.

1. Lead Generation: We’ll build target lists, write scientifically relevant messaging, and send messages on your behalf to book qualified sales meetings with biotech and pharma companies.

2. Training for Teams: If you want to upskill your team around prospecting, driving to close, key account management, AI, or any other topic, we can put together a training plan specific to your organization’s needs.

3. Strategy Call: Need more than training? Want help implementing and executing your sales strategy? In a 30-minute call, we will assess your company’s current situation and identify growth opportunities.